These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 9638394)

  • 41. Drug choices in the treatment of atrial fibrillation.
    Reiffel JA
    Am J Cardiol; 2000 May; 85(10A):12D-19D. PubMed ID: 10822036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single dose of ibutilide for conversion of persistent atrial fibrillation after radiofrequency ablation.
    Hou Y; Fang PH; Liu J; Li XF; Hu JQ; Zhang S
    Chin Med J (Engl); 2011 Mar; 124(5):710-3. PubMed ID: 21518563
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Atrial fibrillation requiring urgent medical care. Approach and outcome in the various departments of admission. Data from the atrial Fibrillation/flutter Italian REgistry (FIRE).
    Santini M; De Ferrari GM; Pandozi C; Alboni P; Capucci A; Disertori M; Gaita F; Lombardi F; Maggioni AP; Mugelli A; Salerno-Uriarte JA; Sermasi S; Schwartz PJ;
    Ital Heart J; 2004 Mar; 5(3):205-13. PubMed ID: 15119503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factors predicting maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation and flutter: a reanalysis with recently acquired data.
    Arnar DO; Danielsen R
    Cardiology; 1996; 87(3):181-8. PubMed ID: 8725311
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The epidemiology and management of recent-onset atrial fibrillation and flutter presenting to the Emergency Department.
    Hamilton A; Clark D; Gray A; Cragg A; Grubb N;
    Eur J Emerg Med; 2015 Jun; 22(3):155-61. PubMed ID: 25203594
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and risk/benefit analysis of ibutilide for acute conversion of atrial fibrillation/flutter.
    Kowey PR; VanderLugt JT; Luderer JR
    Am J Cardiol; 1996 Oct; 78(8A):46-52. PubMed ID: 8903276
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and cost comparison of ibutilide and direct-current cardioversion for atrial fibrillation and flutter.
    Murdock DK; Schumock GT; Kaliebe J; Olson K; Guenette AJ
    Am J Cardiol; 2000 Feb; 85(4):503-6, A11. PubMed ID: 10728961
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ibutilide for rapid conversion of atrial fibrillation or flutter in a mixed critically ill patient population.
    Delle Karth G; Schillinger M; Geppert A; Haumer M; Gwechenberger M; Meyer B; Heinz G; Siostrzonek P
    Wien Klin Wochenschr; 2005 Feb; 117(3):92-7. PubMed ID: 15773423
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of atrial fibrillation and atrial flutter: Part II.
    Aronow WS
    Cardiol Rev; 2008; 16(5):230-9. PubMed ID: 18708824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ibutilide--a new drug for the rapid termination of atrial fibrillation and atrial flutter.
    Kayser SR
    Prog Cardiovasc Nurs; 1997; 12(1):39-43. PubMed ID: 9058463
    [No Abstract]   [Full Text] [Related]  

  • 51. Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat.
    Blaauw Y; Schotten U; van Hunnik A; Neuberger HR; Allessie MA
    Cardiovasc Res; 2007 Jul; 75(1):89-98. PubMed ID: 17466958
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of high doses of magnesium on converting ibutilide to a safe and more effective agent.
    Patsilinakos S; Christou A; Kafkas N; Nikolaou N; Antonatos D; Katsanos S; Spanodimos S; Babalis D
    Am J Cardiol; 2010 Sep; 106(5):673-6. PubMed ID: 20723644
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical comparison of ibutilide and propafenone for converting atrial flutter.
    Sun JL; Guo JH; Zhang N; Zhang HC; Zhang P
    Cardiovasc Drugs Ther; 2005 Jan; 19(1):57-64. PubMed ID: 15883757
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New antiarrhythmic agents for atrial fibrillation and atrial flutter: United States drug market response as an indicator of acceptance.
    LaPointe NM; Pamer CA; Kramer JM
    Pharmacotherapy; 2003 Oct; 23(10):1316-21. PubMed ID: 14594348
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Refralon (niferidil) is a new class III antiarrhythmic agent for pharmacological cardioversion for persistent atrial fibrillation and atrial flutter].
    Maykov EB; Yuricheva YA; Mironov NY; Sokolov SF; Golitsyn SP; Rozenshtraukh LV; Chazov EI
    Ter Arkh; 2015; 87(1):38-48. PubMed ID: 25823268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Successful termination of atrial flutter by ibutilide during pregnancy.
    Burkart TA; Kron J; Miles WM; Conti JB; Gonzalez MD
    Pacing Clin Electrophysiol; 2007 Feb; 30(2):283-6. PubMed ID: 17338730
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Predictors of conversion to sinus rhythm using ibutilide for atrial fibrillation or flutter.
    Zaqqa M; Afshar H; Rasekh A; Khoshnevis R; Vaughn WK; Massumi A
    Am J Cardiol; 2000 Jan; 85(1):112-4, A9. PubMed ID: 11078250
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dofetilide: a new drug to control cardiac arrhythmia.
    Elming H; Brendorp B; Pedersen OD; Køber L; Torp-Petersen C
    Expert Opin Pharmacother; 2003 Jun; 4(6):973-85. PubMed ID: 12783593
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Pharmacological therapy of atrial fibrillation and atrial flutter].
    Grönefeld GC; Li YG; Hohnloser SH
    Herz; 2002 Jun; 27(4):329-44. PubMed ID: 12187863
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacologic conversion of atrial fibrillation and atrial flutter to normal sinus rhythm: the role of ibutilide.
    Katcher MS; Estes NA
    Pharmacotherapy; 1997; 17(1):177-80. PubMed ID: 9017781
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.